Last reviewed · How we verify

FLUTICASONE PROPRIONATE

University of Dundee · FDA-approved active Small molecule Quality 2/100

FLUTICASONE PROPRIONATE is a Small molecule drug developed by University of Dundee. It is currently FDA-approved. Also known as: Treatment.

At a glance

Generic nameFLUTICASONE PROPRIONATE
Also known asTreatment
SponsorUniversity of Dundee
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about FLUTICASONE PROPRIONATE

What is FLUTICASONE PROPRIONATE?

FLUTICASONE PROPRIONATE is a Small molecule drug developed by University of Dundee.

Who makes FLUTICASONE PROPRIONATE?

FLUTICASONE PROPRIONATE is developed and marketed by University of Dundee (see full University of Dundee pipeline at /company/university-of-dundee).

Is FLUTICASONE PROPRIONATE also known as anything else?

FLUTICASONE PROPRIONATE is also known as Treatment.

What development phase is FLUTICASONE PROPRIONATE in?

FLUTICASONE PROPRIONATE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing